New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
| Autor: | Calabrese P; Division of Molecular and Cognitive Neuroscience, Department of Psychology, University of Basel, Basel, Switzerland., Kobelt G; European Health Economics, Mulhouse, France., Berg J; Mapi Group, Stockholm, Sweden., Capsa D; Mapi Group, Stockholm, Sweden., Eriksson J; Mapi Group, Stockholm, Sweden. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2017 Aug; Vol. 23 (2_suppl), pp. 192-203. |
| DOI: | 10.1177/1352458517708685 |
| Abstrakt: | Introduction: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and Methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in CHF 2015. Results: A total of 721 patients (mean age 48 years) participated in Switzerland; 90% were below retirement age, and of these, 65% were employed. Employment was related to disease severity, and MS affected productivity at work for 69% of patients. Overall, 93% and 64% of patients experienced fatigue and cognition as a problem, respectively. The mean utility and annual costs were 0.799 and 29,600CHF at Expanded Disability Status Scale (EDSS) 0-3, 0.614 and 66,800CHF at EDSS 4-6.5 and 0.348 and 110,800CHF at EDSS 7-9, respectively. The mean cost of a relapse was estimated at 7600CHF. Conclusion: This study provides current data on MS in Switzerland that are important for development of health policies and to estimate the value of current and future treatments. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|